Cefepime Dosing for Cellulitis
For this 74-year-old male with cellulitis, normal renal function (CrCl 100 mL/min), and weight 71.4 kg, administer cefepime 2 g IV every 8 hours as a 30-minute to 3-hour infusion.
Rationale for Dosing
Standard Dosing Considerations
The FDA label indicates standard cefepime dosing is 2 g every 12 hours for patients with CrCl ≥60 mL/min 1. However, this patient's preserved renal function (CrCl 100 mL/min) creates a critical pharmacokinetic challenge that requires dose intensification.
Why Standard Dosing May Be Inadequate
Patients with CrCl ≥100 mL/min demonstrate significantly increased cefepime clearance and lower trough concentrations 2. Research shows that patients with CrCl >100 mL/min had mean trough levels of only 3.3 ± 3.6 mg/L compared to 19.5 ± 21.5 mg/L in those with CrCl 60-100 mL/min 2. This represents an 85% reduction in trough concentrations, potentially compromising bactericidal activity.
Pharmacodynamic Target Requirements
Cefepime efficacy depends on maintaining free drug concentrations above the MIC for ≥65-70% of the dosing interval (fT>MIC) 3, 4. For cellulitis caused by susceptible organisms (typically Staphylococcus aureus and Streptococcus with MICs ≤4 mg/L), standard dosing achieves adequate coverage 5. However:
- Standard 2 g every 12 hours may be suboptimal in patients with augmented renal clearance
- Studies demonstrate that only 45-65% of patients achieve adequate coverage for pathogens with MIC ≥8 mg/L on standard dosing 6
- Patients with CrCl >100 mL/min specifically struggle to maintain therapeutic concentrations 2, 7
Recommended Dosing Strategy
Primary Recommendation: 2 g Every 8 Hours
Administer cefepime 2 g IV every 8 hours as either:
- 30-minute infusion (standard approach) 1
- 3-hour extended infusion (preferred for optimizing PK/PD parameters) 8
This regimen:
- Compensates for augmented renal clearance at CrCl 100 mL/min
- Achieves >70% fT>MIC for organisms with MIC ≤4 mg/L 5
- Maintains adequate trough concentrations throughout the dosing interval
- Remains within safe exposure limits (trough <20-30 mg/L) to avoid neurotoxicity 6, 3
Alternative Consideration
If resources permit and clinical severity warrants, 1 g every 4 hours has been shown to maintain concentrations above MIC breakpoints for 92-100% of the dosing interval in patients with augmented renal clearance 7. However, this is off-label and logistically challenging.
Critical Safety Considerations
Monitoring for Neurotoxicity
While this patient has normal renal function, elderly patients (≥65 years) are at higher risk for cefepime-related adverse events 1. Monitor for:
- Confusion or altered mental status
- Myoclonus or muscle jerks
- Seizures
- Non-convulsive status epilepticus
These symptoms may occur even with appropriate dose adjustment and can be subtle and easily missed 6. If neurological symptoms develop, immediately check cefepime trough levels and consider discontinuation if levels exceed 20-30 mg/L.
Renal Function Monitoring
Reassess renal function every 2-3 days during therapy 1. If CrCl decreases to <60 mL/min, adjust to 2 g every 12 hours or every 24 hours depending on severity of decline 1.
Duration of Therapy
For uncomplicated cellulitis, treat for 5-7 days 9. Extend therapy only if clinical improvement is not evident by day 5 9. The evidence supports shorter courses (5-6 days) as equally effective as traditional 10-12 day regimens for cellulitis 9.
Common Pitfalls to Avoid
- Do not use standard 2 g every 12 hours dosing in this patient with CrCl 100 mL/min—this will likely result in subtherapeutic concentrations
- Do not assume normal renal function means standard dosing is adequate—augmented clearance requires dose intensification
- Do not overlook subtle neurological changes in elderly patients, even with appropriate dosing
- Do not continue therapy beyond 7 days without documented lack of clinical response